Effects of an e-Home Based Symptom Management and Mindfulness Training Programme on QoL in Breast Cancer Survivors
22 сентября 2020 г. обновлено: Karis Cheng, National University of Singapore
Effects of an e-Home Based Symptom Management and Mindfulness Training Programme on Quality of Life in Breast Cancer Survivors
Breast cancer is the most common cancer in women in Singapore.
Breast cancer survivors usually experience side effects/symptoms after surgery and/or adjuvant chemotherapy and/or radiotherapy such as fatigue, lymphedema, problems with sleeping, peripheral neuropathy, and anxiety/depression.
Currently, there is no study to include both symptom management and mindfulness training components for breast cancer survivors.
And given breast cancer survivors have infrequent clinical follow-up, we aim to develop an e-Home based symptom management and mindfulness training programme for breast cancer survivors and to determine its effects on quality of life, symptom distress, psychosocial adjustment, psychological morbidity, and unplanned outpatient attendance or hospitalisation in breast cancer survivors.
We employ a randomised clinical trial with four study arms (with 47 subjects in each arm) together with a process evaluation; group 1 (usual care), group 2 (experimental group: five weekly sessions of online symptom management + mindfulness training programme and usual care), group 3 (comparison group 1: five weekly sessions of online symptom management programme and usual care), and group 4 (comparison group 2: five weekly sessions of online mindfulness training programme and usual care).
Subjects will complete questionnaires measures of 6-item Social Support Questionnaire, Breast Cancer Survivor Self-Efficacy Scale, the Quality of Life-Cancer Survivor Scale, Memorial Symptom Assessment Scale, Psychosocial Adjustment to Illness Scale, short version of the Fear of Recurrence Scale, Hospital and anxiety Depression Scale and Five Facet Mindfulness Questionnaire at baseline (printed questionnaires), at 8 weeks from baseline, at 12 weeks from baseline and at 24 weeks from baseline by an online system or printed questionnaires.
Individualised semi-structured interview (15-25 mins) for experimental and comparison groups will be conducted at 24 weeks from baseline to understand the subjects' experiences of the study programme.
Data will be analysed using SPSS version 24.
Baseline demographic and clinical information of subjects in the experimental, comparison and control groups will be summarised using descriptive statistics, and will be compared using chi square tests and ANOVA/ANCOVA tests.
Intention-to-treat approach will be used.
Repeated measures analysis of variance will be used to examine the differences on outcome measures among the experimental, comparison and control groups across study time points.
In addition, differences in changes in outcome measures among experimental, comparison groups and usual care groups will be tested using multilevel modelling techniques.
A p-value smaller than 5% will be considered as statistically significant.
Content analysis will be conducted to analyse the interviews data.
Обзор исследования
Статус
Завершенный
Условия
Вмешательство/лечение
Тип исследования
Интервенционный
Регистрация (Действительный)
172
Фаза
- Непригодный
Контакты и местонахождение
В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.
Места учебы
-
-
-
Singapore, Сингапур
- National University Hospital
-
Singapore, Сингапур
- National Cancer Centre Singapore
-
-
Критерии участия
Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.
Критерии приемлемости
Возраст, подходящий для обучения
От 21 год до 100 лет (Взрослый, Пожилой взрослый)
Принимает здоровых добровольцев
Нет
Полы, имеющие право на обучение
Женский
Описание
Inclusion Criteria:
- women aged 21 or above
- able to speak and read English
- diagnosed with breast cancer stage 0 to 3 for the first time
- have completed cancer treatment including breast surgery and/or adjuvant chemotherapy and/or radiotherapy between 6 months to 5 years previously
- with and without ongoing HER2 target therapy (e.g.: Herceptin) and/or hormonal therapy
- with ECOG Performance Status score of 0 to 1
- able to understand the study and give informed consent
- have access to the internet through a handheld device
Exclusion Criteria:
- they are illiterate
- have serious psychiatric disorders (e.g. schizophrenia, dementia, and intellectual disabilities)
- with ECOG Performance Status score of 2 or above
Учебный план
В этом разделе представлена подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.
Как устроено исследование?
Детали дизайна
- Основная цель: Поддерживающая терапия
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Без вмешательства: Usual care group
Usual care is meant the routine medical and health care services at the hospital.
|
|
|
Экспериментальный: Experimental group
Five weekly sessions of online symptom management + mindfulness training programme + usual care
|
5 weekly sessions of online self-administered mindfulness training programme in which they will receive audio-recorded and video-recorded instructions, pictorial or text-based instructions for various mindfulness exercises such as body scan meditation, mindful breathing and walking meditation.
5 weekly online education module in which they will receive video-recorded, audio-recorded, pictorial or text-based instructions for various self-management strategies.
Topics include fatigue, pain, numbness/tingling, lymphedema, anxiety/depression, and problems with sleeping.
|
|
Активный компаратор: Comparison group 1
Five weekly sessions of online symptom management programme + usual care
|
5 weekly online education module in which they will receive video-recorded, audio-recorded, pictorial or text-based instructions for various self-management strategies.
Topics include fatigue, pain, numbness/tingling, lymphedema, anxiety/depression, and problems with sleeping.
|
|
Активный компаратор: Comparison group 2
Five weekly sessions of online mindfulness training programme and usual care
|
5 weekly sessions of online self-administered mindfulness training programme in which they will receive audio-recorded and video-recorded instructions, pictorial or text-based instructions for various mindfulness exercises such as body scan meditation, mindful breathing and walking meditation.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Временное ограничение |
|---|---|
|
Change from baseline quality of life score at 8 weeks
Временное ограничение: Change between baseline and at 8 weeks
|
Change between baseline and at 8 weeks
|
|
Change from baseline quality of life score at 12 weeks
Временное ограничение: Change between baseline and at 12 weeks
|
Change between baseline and at 12 weeks
|
|
Change from baseline quality of life score at 24 weeks
Временное ограничение: Change between baseline and at 24 weeks
|
Change between baseline and at 24 weeks
|
Вторичные показатели результатов
Мера результата |
Временное ограничение |
|---|---|
|
Change from baseline social support score at 8 weeks
Временное ограничение: Change between baseline and at 8 weeks
|
Change between baseline and at 8 weeks
|
|
Change from baseline social support score at 12 weeks
Временное ограничение: Change between baseline and at 12 weeks
|
Change between baseline and at 12 weeks
|
|
Change from baseline social support score at 24 weeks
Временное ограничение: Change between baseline and at 24 weeks
|
Change between baseline and at 24 weeks
|
|
Change from baseline self-efficacy score at 8 weeks
Временное ограничение: Change between baseline and at 8 weeks
|
Change between baseline and at 8 weeks
|
|
Change from baseline self-efficacy score at 12 weeks
Временное ограничение: Change between baseline and at 12 weeks
|
Change between baseline and at 12 weeks
|
|
Change from baseline self-efficacy score at 24 weeks
Временное ограничение: Change between baseline and at 24 weeks
|
Change between baseline and at 24 weeks
|
|
Change from baseline symptom score at 8 weeks
Временное ограничение: Change between baseline and at 8 weeks
|
Change between baseline and at 8 weeks
|
|
Change from baseline symptom score at 12 weeks
Временное ограничение: Change between baseline and at 12 weeks
|
Change between baseline and at 12 weeks
|
|
Change from baseline symptom score at 24 weeks
Временное ограничение: Change between baseline and at 24 weeks
|
Change between baseline and at 24 weeks
|
|
Change from baseline psychosocial adjustment to illness score at 8 weeks
Временное ограничение: Change between baseline and at 8 weeks
|
Change between baseline and at 8 weeks
|
|
Change from baseline psychosocial adjustment to illness score at 12 weeks
Временное ограничение: Change between baseline and at 12 weeks
|
Change between baseline and at 12 weeks
|
|
Change from baseline psychosocial adjustment to illness score at 24 weeks
Временное ограничение: Change between baseline and at 24 weeks
|
Change between baseline and at 24 weeks
|
|
Change from baseline fear of recurrence score at 8 weeks
Временное ограничение: Change between baseline and at 8 weeks
|
Change between baseline and at 8 weeks
|
|
Change from baseline fear of recurrence score at 12 weeks
Временное ограничение: Change between baseline and at 12 weeks
|
Change between baseline and at 12 weeks
|
|
Change from baseline fear of recurrence score at 24 weeks
Временное ограничение: Change between baseline and at 24 weeks
|
Change between baseline and at 24 weeks
|
|
Change from baseline anxiety and depression score at 8 weeks
Временное ограничение: Change between baseline and at 8 weeks
|
Change between baseline and at 8 weeks
|
|
Change from baseline anxiety and depression score at 12 weeks
Временное ограничение: Change between baseline and at 12 weeks
|
Change between baseline and at 12 weeks
|
|
Change from baseline anxiety and depression score at 24 weeks
Временное ограничение: Change between baseline and at 24 weeks
|
Change between baseline and at 24 weeks
|
|
Change from baseline mindfulness score at 8 weeks
Временное ограничение: Change between baseline and at 8 weeks
|
Change between baseline and at 8 weeks
|
|
Change from baseline mindfulness score at 12 weeks
Временное ограничение: Change between baseline and at 12 weeks
|
Change between baseline and at 12 weeks
|
|
Change from baseline mindfulness score at 24 weeks
Временное ограничение: Change between baseline and at 24 weeks
|
Change between baseline and at 24 weeks
|
Соавторы и исследователи
Здесь вы найдете людей и организации, участвующие в этом исследовании.
Спонсор
Следователи
- Главный следователь: Karis Cheng, National University of Singapore
Публикации и полезные ссылки
Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.
Общие публикации
- Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. doi: 10.1111/j.1600-0447.1983.tb09716.x.
- Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, Sobel K, Coyle N, Kemeny N, Norton L, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30A(9):1326-36. doi: 10.1016/0959-8049(94)90182-1.
- Baer RA, Smith GT, Hopkins J, Krietemeyer J, Toney L. Using self-report assessment methods to explore facets of mindfulness. Assessment. 2006 Mar;13(1):27-45. doi: 10.1177/1073191105283504.
- Bower JE, Ganz PA, Desmond KA, Bernaards C, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer. 2006 Feb 15;106(4):751-8. doi: 10.1002/cncr.21671.
- Champion VL, Ziner KW, Monahan PO, Stump TE, Cella D, Smith LG, Bell CJ, Von Ah D, Sledge GW. Development and psychometric testing of a breast cancer survivor self-efficacy scale. Oncol Nurs Forum. 2013 Nov;40(6):E403-10. doi: 10.1188/13.ONF.E403-E410.
- Ferrell BR, Dow KH, Grant M. Measurement of the quality of life in cancer survivors. Qual Life Res. 1995 Dec;4(6):523-31. doi: 10.1007/BF00634747.
- Cheng KK, Darshini Devi R, Wong WH, Koh C. Perceived symptoms and the supportive care needs of breast cancer survivors six months to five years post-treatment period. Eur J Oncol Nurs. 2014 Feb;18(1):3-9. doi: 10.1016/j.ejon.2013.10.005. Epub 2013 Dec 5.
Даты записи исследования
Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.
Изучение основных дат
Начало исследования (Действительный)
6 декабря 2016 г.
Первичное завершение (Действительный)
14 марта 2020 г.
Завершение исследования (Действительный)
14 марта 2020 г.
Даты регистрации исследования
Первый отправленный
10 октября 2016 г.
Впервые представлено, что соответствует критериям контроля качества
11 октября 2016 г.
Первый опубликованный (Оценивать)
13 октября 2016 г.
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
23 сентября 2020 г.
Последнее отправленное обновление, отвечающее критериям контроля качества
22 сентября 2020 г.
Последняя проверка
1 сентября 2020 г.
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- R-545-000-073-592
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
НЕТ
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .